[European guidelines on heart failure: pharmacotherapy]. / Europäische Leitlinien Herzinsuffizienz: medikamentöse Therapie.
Herz
; 48(2): 89-94, 2023 Mar.
Article
em De
| MEDLINE
| ID: mdl-36695878
ABSTRACT
The new 2021 guidelines of the European Society of Cardiology (ESC) have broken with the old step by step treatment of heart failure and have fundamentally revised the strategy in the pharmacotherapy setting. For patients with heart failure and reduced ejection fraction ≤â¯40%, the 4 substance groups angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor-neprilysin inhibitors (ARNI), beta blockers, mineralocorticoid receptor antagonists (MRA) and sodium-glucose transporter 2 (SGLT2) inhibitors are now recommended as early as possible after diagnosis. Completing the substance groups has priority over increasing the dosage of the individual substances. This makes it necessary to rethink current clinical practice, especially as the guidelines are reluctant to give concrete instructions for implementation.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Cardiologia
/
Disfunção Ventricular Esquerda
/
Insuficiência Cardíaca
Tipo de estudo:
Guideline
Limite:
Humans
Idioma:
De
Ano de publicação:
2023
Tipo de documento:
Article